This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the long-term effects of pharmacologically induced reduction in body weight in hypertensive patients with orlistat, sibutramine or rimonabant on:
- all cause mortality
- cardiovascular morbidity
- adverse events
- changes in systolic and/or diastolic blood pressure
- body weight reduction
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.